Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 ORGN001 dose-escalation study in pediatric molybdenum cofactor deficiency type A
NL-OMON55625Phase 2Recruiting
- Sponsor
- Origin Biosciences, Inc.
- Start
- Apr 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosdenopterin in molybdenum cofactor deficiency type A (MoCD-A), sponsored by Origin Biosciences, Inc. Primary endpoint: Safety over the first 6 months of treatment. Started Apr 2015; status: recruiting.
02
Drugs
fosdenopterin
03
Conditions
molybdenum cofactor deficiency type A (MoCD-A)
Beyond the preview
Go deeper on NL-OMON55625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55625.